Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae to Present at the Bank of America Merrill Lynch 2017 Health Care Conference

Invitae to Present at the Bank of America Merrill Lynch 2017 Health Care Conference

April 27, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer, will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Thursday, May 18, 2017 at 10:40 a.m. Pacific in Las Vegas. Sean George will also participate in a panel discussion titled “Genetic Testing - Pricing, Payment and Policy in a Rapidly Growing Space” on Wednesday, May 17 at 4:20 p.m. Pacific.

The live ...

Read more


Invitae to Announce First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017

Invitae to Announce First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017

April 24, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its first quarter 2017 financial results on Monday, May 8, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for ...

Read more


Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screening

Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screening

April 20, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the addition of 80 new panels alongside updates to an additional 24 panels for the diagnosis of inherited immunologic and metabolic disorders, including panels designed to confirm diagnoses suggested by newborn screening. The new and updated tests further expand the company’s robust menu of high-quality, affordable diagnostic genetic tests available for use by clinicians.

Many inherited metabolic disorders, such as lysosomal storage disorders, are caused ...

Read more


Invitae expands its Genome Network with the launch of the Invitae Patient Insights Network (PIN), enabling participants to share health information and contribute to research

Invitae expands its Genome Network with the launch of the Invitae Patient Insights Network (PIN), enabling participants to share health information and contribute to research

April 06, 2017

A new approach to a patient registry, the Invitae PIN connects patients, clinicians, researchers, and biopharma therapeutics developers

Permission-based, patient-centric network designed to connect patients to potential treatments and accelerate scientific discovery

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the launch of the Invitae Patient Insights Network‚Ą†, a permission-based, patient-centered network designed to make it easy for patients to share health experiences, contribute de-identified clinical data, and maintain their privacy while being connected ...

Read more


Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis

Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis

April 03, 2017

Offered through Invitae’s Genome Network, program drives early diagnosis to help patients and their clinicians make more informed decisions about their health

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has announced a program in partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing for hereditary ATTR (hATTR) amyloidosis, a rare, progressive and life-threatening disease caused by a mutation in the TTR gene which causes accumulation of misfolded proteins in nerves ...

Read more


Invitae announces introduction of exome testing

Invitae announces introduction of exome testing

March 30, 2017

Exome testing expands company’s menu, offering an important tool for diagnosing a wide array of genetic disorders

Test menu now includes more than 20,000 genes

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced a major expansion of its genetic testing services with the introduction of exome sequencing and interpretation services, bringing the company’s available test menu to more than 20,000 genes. The Invitae Boosted Exome offers high-quality testing tailored to ...

Read more


Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults

Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults

March 23, 2017

Research outlining medically actionable approach, patient experiences in pilot program presented at American College of Medical Genetics Annual Clinical Genetics Meeting

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has expanded the menu of tests offered as part of its ongoing proactive genetic testing pilot program. The announcement was made during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix, where Invitae researchers also presented findings from the company ...

Read more


Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting

Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting

March 22, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the availability of a new genetic test for the diagnosis of Spinal Muscular Atrophy (SMA), a neuromuscular disease that is one of the leading lethal genetic disorders among infants as well as a significant cause of progressive neuromuscular disease in childhood. The new test, announced during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, features a novel, custom methodology that offers significant improvements ...

Read more


Invitae to present seventeen posters and presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting

Invitae to present seventeen posters and presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting

March 14, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it will be presenting seventeen posters and presentations at the 2017 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix.

“Scientific understanding of genetic medicine continues to expand rapidly, making sessions such as the ACMG meeting essential for the genetics community,” said Robert Nussbaum, MD, chief medical officer of Invitae. “The research we will be presenting at ACMG this year has implications for ...

Read more


Invitae to present at the Cowen and Company 37th Annual Health Care Conference

Invitae to present at the Cowen and Company 37th Annual Health Care Conference

February 21, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that members of the company’s management team will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 at approximately 4:00 p.m. Eastern / 1:00 p.m. Pacific in Boston, Massachusetts.

The live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay ...

Read more

Invitae’s Mission

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice in order to improve healthcare for billions of people. There are three stages to Invitae’s business model:

  1. Make genetic testing more affordable and accessible than ever before.
  2. Build a secure and trusted genome management infrastructure with which we help individuals manage their own genetic information over the course of their life.
  3. Design a genome network, a global community for sharing genetic information to advance science and medicine and allow patients, doctors and organizations to connect around genetic conditions.

Invitae’s four core principles

  1. Patients should own and control their own genetic information.
  2. Healthcare professionals are fundamental in ordering and interpreting genetic information.
  3. Driving down the price of genetic information will increase that information’s clinical and personal utility.
  4. Genetic information is more valuable when shared.

About Invitae

Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas.

For more information, visit out website at ir.invitae.com and follow us on Twitter: @invitae and @invitaeIR